The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) is a huge mover today! About 210,621 shares traded hands. Asterias Biotherapeutics Inc (NYSEMKT:AST) has declined 23.77% since March 9, 2016 and is downtrending. It has underperformed by 31.19% the S&P500.
The move comes after 7 months negative chart setup for the $161.07 million company. It was reported on Oct, 12 by Barchart.com. We have $3.35 PT which if reached, will make NYSEMKT:AST worth $16.11 million less.
Analysts await Asterias Biotherapeutics Inc (NYSEMKT:AST) to report earnings on November, 14. They expect $-0.20 earnings per share, down 53.85% or $0.07 from last year’s $-0.13 per share. After $-0.16 actual earnings per share reported by Asterias Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage
Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, August 11 by MLV. Chardan Capital Markets initiated Asterias Biotherapeutics Inc (NYSEMKT:AST) on Monday, May 23 with “Buy” rating. FBR Capital initiated it with “Outperform” rating and $10 target price in Thursday, November 19 report. The rating was upgraded by Zacks to “Hold” on Thursday, September 3.
According to Zacks Investment Research, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California.”
More notable recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: Prnewswire.com which released: “Asterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical …” on September 07, 2016, also Prnewswire.com with their article: “Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief …” published on February 29, 2016, Prnewswire.com published: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” on March 31, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) were released by: Prnewswire.com and their article: “Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR …” published on September 27, 2016 as well as Prnewswire.com‘s news article titled: “Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with …” with publication date: September 14, 2016.
AST Company Profile
Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.